MEDIF Quote, Financials, Valuation and Earnings

Edesa Biotech, Inc. has a net margin of -18.71% compared to MediPharm Labs Corp.'s net margin of --. MediPharm Labs Corp.'s return on equity of -19.3% beat Edesa Biotech, Inc.'s return on equity of -77.48%.

MediPharm Labs Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Edesa Biotech, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 746.15%. Given that Edesa Biotech, Inc. has higher upside potential than MediPharm Labs Corp., analysts believe Edesa Biotech, Inc. is more attractive than MediPharm Labs Corp..

MediPharm Labs Corp. has a beta of 0.510, which suggesting that the stock is 49.004% less volatile than S&P 500. In comparison Edesa Biotech, Inc. has a beta of 0.078, suggesting its less volatile than the S&P 500 by 92.204%.

MediPharm Labs Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edesa Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MediPharm Labs Corp. pays -- of its earnings as a dividend. Edesa Biotech, Inc. pays out -- of its earnings as a dividend.

MediPharm Labs Corp. quarterly revenues are $8.3M, which are larger than Edesa Biotech, Inc. quarterly revenues of --. MediPharm Labs Corp.'s net income of -$1.6M is higher than Edesa Biotech, Inc.'s net income of -$2.2M. Notably, MediPharm Labs Corp.'s price-to-earnings ratio is -- while Edesa Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MediPharm Labs Corp. is 0.69x versus 31.22x for Edesa Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Lexaria Bioscience Corp. has a net margin of -18.71% compared to MediPharm Labs Corp.'s net margin of -2178.51%. MediPharm Labs Corp.'s return on equity of -19.3% beat Lexaria Bioscience Corp.'s return on equity of -147.19%.

MediPharm Labs Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Lexaria Bioscience Corp. has an analysts' consensus of $5.33 which suggests that it could grow by 852.38%. Given that Lexaria Bioscience Corp. has higher upside potential than MediPharm Labs Corp., analysts believe Lexaria Bioscience Corp. is more attractive than MediPharm Labs Corp..

MediPharm Labs Corp. has a beta of 0.510, which suggesting that the stock is 49.004% less volatile than S&P 500. In comparison Lexaria Bioscience Corp. has a beta of 0.628, suggesting its less volatile than the S&P 500 by 37.221%.

MediPharm Labs Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lexaria Bioscience Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MediPharm Labs Corp. pays -- of its earnings as a dividend. Lexaria Bioscience Corp. pays out -- of its earnings as a dividend.

MediPharm Labs Corp. quarterly revenues are $8.3M, which are larger than Lexaria Bioscience Corp. quarterly revenues of $174K. MediPharm Labs Corp.'s net income of -$1.6M is higher than Lexaria Bioscience Corp.'s net income of -$2.7M. Notably, MediPharm Labs Corp.'s price-to-earnings ratio is -- while Lexaria Bioscience Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MediPharm Labs Corp. is 0.69x versus 14.29x for Lexaria Bioscience Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Oncolytics Biotech, Inc. has a net margin of -18.71% compared to MediPharm Labs Corp.'s net margin of --. MediPharm Labs Corp.'s return on equity of -19.3% beat Oncolytics Biotech, Inc.'s return on equity of -635.07%.

MediPharm Labs Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Oncolytics Biotech, Inc. has an analysts' consensus of $5.55 which suggests that it could grow by 472.27%. Given that Oncolytics Biotech, Inc. has higher upside potential than MediPharm Labs Corp., analysts believe Oncolytics Biotech, Inc. is more attractive than MediPharm Labs Corp..

MediPharm Labs Corp. has a beta of 0.510, which suggesting that the stock is 49.004% less volatile than S&P 500. In comparison Oncolytics Biotech, Inc. has a beta of 0.880, suggesting its less volatile than the S&P 500 by 11.965%.

MediPharm Labs Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oncolytics Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MediPharm Labs Corp. pays -- of its earnings as a dividend. Oncolytics Biotech, Inc. pays out -- of its earnings as a dividend.

MediPharm Labs Corp. quarterly revenues are $8.3M, which are larger than Oncolytics Biotech, Inc. quarterly revenues of --. MediPharm Labs Corp.'s net income of -$1.6M is higher than Oncolytics Biotech, Inc.'s net income of -$10.5M. Notably, MediPharm Labs Corp.'s price-to-earnings ratio is -- while Oncolytics Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MediPharm Labs Corp. is 0.69x versus -- for Oncolytics Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Xenon Pharmaceuticals, Inc. has a net margin of -18.71% compared to MediPharm Labs Corp.'s net margin of -867.29%. MediPharm Labs Corp.'s return on equity of -19.3% beat Xenon Pharmaceuticals, Inc.'s return on equity of -44.39%.

MediPharm Labs Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Xenon Pharmaceuticals, Inc. has an analysts' consensus of $55.40 which suggests that it could grow by 23.09%. Given that Xenon Pharmaceuticals, Inc. has higher upside potential than MediPharm Labs Corp., analysts believe Xenon Pharmaceuticals, Inc. is more attractive than MediPharm Labs Corp..

MediPharm Labs Corp. has a beta of 0.510, which suggesting that the stock is 49.004% less volatile than S&P 500. In comparison Xenon Pharmaceuticals, Inc. has a beta of 1.027, suggesting its more volatile than the S&P 500 by 2.689%.

MediPharm Labs Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xenon Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MediPharm Labs Corp. pays -- of its earnings as a dividend. Xenon Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

MediPharm Labs Corp. quarterly revenues are $8.3M, which are larger than Xenon Pharmaceuticals, Inc. quarterly revenues of --. MediPharm Labs Corp.'s net income of -$1.6M is higher than Xenon Pharmaceuticals, Inc.'s net income of -$90.9M. Notably, MediPharm Labs Corp.'s price-to-earnings ratio is -- while Xenon Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MediPharm Labs Corp. is 0.69x versus 473.02x for Xenon Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.